KISSEI PHARMACEUTICAL CO.,LTD. Logo

KISSEI PHARMACEUTICAL CO.,LTD.

Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.

4547 | T

Overview

Corporate Details

ISIN(s):
JP3240600001
LEI:
Country:
Japan
Address:
松本市芳野19番48号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kissei Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company engaged in the development, manufacturing, and commercialization of innovative medicines. The company strategically focuses its research and development efforts on specific therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its business model integrates in-house drug discovery with strategic partnerships, such as in-licensing and out-licensing agreements, to build a robust product pipeline. Kissei's portfolio comprises both specialty and generic drugs, aiming to address unmet medical needs and contribute to the health of people globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 08:34
Interim Report
確認書
Japanese 8.9 KB
2025-11-10 08:33
Interim Report
半期報告書-第81期(2025/04/01-2026/03/31)
Japanese 236.4 KB
2025-06-27 06:00
Post-Annual General Meeting Information
臨時報告書
Japanese 23.3 KB
2025-06-24 06:01
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 06:01
Governance Information
内部統制報告書-第80期(2024/04/01-2025/03/31)
Japanese 25.5 KB
2025-06-24 06:00
Annual Report
有価証券報告書-第80期(2024/04/01-2025/03/31)
Japanese 1.5 MB
2025-06-11 06:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2024-12-27 08:00
Major Shareholding Notification
大量保有報告書
Japanese 38.5 KB
2024-12-13 05:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-11-13 05:01
Interim Report
確認書
Japanese 9.0 KB
2024-11-13 05:00
Interim Report
半期報告書-第80期(2024/04/01-2025/03/31)
Japanese 240.5 KB
2024-06-28 06:00
Post-Annual General Meeting Information
臨時報告書
Japanese 29.4 KB
2024-06-25 06:01
Governance Information
内部統制報告書-第79期(2023/04/01-2024/03/31)
Japanese 23.8 KB
2024-06-25 06:00
Registration Form
確認書
Japanese 9.0 KB
2024-06-25 06:00
Registration Form
有価証券報告書-第79期(2023/04/01-2024/03/31)
Japanese 1.5 MB

Automate Your Workflow. Get a real-time feed of all KISSEI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KISSEI PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KISSEI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America
ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan
4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden
ANNX
Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB

Talk to a Data Expert

Have a question? We'll get back to you promptly.